NovoCure Ltd (NVCR) · Insider trading
What NovoCure's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$3.25M
14 insiders, 0% under a plan
Net, 12 months
−$3.25M
bought less sold
Latest filing
2026-07-01
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Leonard Frank XChief Executive Officer | – | $1.80M | 12 | 2026-06-04 | 459,520 |
| Cordova AshleyChief Executive Officer | $996,541 | $304,163 | 5 | 2025-09-05 | 437,569 |
| Doyle William FDirector, Executive Chairman | – | $933,086 | 2 | 2026-03-03 | 349,727 |
| Paravasthu MukundChief Operating Officer | – | $809,917 | 12 | 2026-03-05 | 72,832 |
| Weinberg UriChf Medical and Innovation Ofr | – | $324,227 | 6 | 2026-03-04 | 267,190 |
| Brackmann ChristophChief Financial Officer | $231,800 | $85,344 | 4 | 2026-03-04 | 182,842 |
| Puri Michal NathChief Human Resources Officer | – | $74,886 | 5 | 2026-03-04 | 201,322 |
| Vernon W AnthonyDirector | – | $63,775 | 2 | 2026-06-02 | 197,657 |
| Scannell Timothy JDirector | – | $63,745 | 2 | 2026-06-02 | 14,288 |
| Leung GabrielDirector | – | $63,735 | 2 | 2026-06-02 | 89,499 |
| Hung DavidDirector | – | $63,725 | 2 | 2026-06-02 | 20,465 |
| Ocean Allyson JDirector | – | $63,715 | 2 | 2026-06-02 | 11,324 |
| Stafford KristinDirector | – | $63,705 | 2 | 2026-06-02 | 11,324 |
| Hilleman Jeryl LDirector | – | $63,685 | 2 | 2026-06-02 | 13,861 |
| Leupin NicolasFormer Chief Medical Officer | – | $48,539 | 4 | 2026-03-04 | 102,979 |
| Madden Martin J.Director | – | $17,173 | 1 | 2025-06-03 | 18,674 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Leonard Frank XChief Executive Officer | Sale | 34,273 | 17.93 | $614,515 | 459,520 | Form 4 |
| 2026-06-02 | Hilleman Jeryl LDirector | Sale | 2,945 | 15.77 | $46,443 | 13,861 | Form 4 |
| 2026-06-02 | Leung GabrielDirector | Sale | 2,945 | 15.77 | $46,443 | 89,499 | Form 4 |
| 2026-06-02 | Hung DavidDirector | Sale | 2,945 | 15.77 | $46,443 | 20,465 | Form 4 |
| 2026-06-02 | Vernon W AnthonyDirector | Sale | 2,945 | 15.77 | $46,443 | 197,657 | Form 4 |
| 2026-06-02 | Scannell Timothy JDirector | Sale | 2,945 | 15.77 | $46,443 | 14,288 | Form 4 |
| 2026-06-02 | Ocean Allyson JDirector | Sale | 2,945 | 15.77 | $46,443 | 11,324 | Form 4 |
| 2026-06-02 | Stafford KristinDirector | Sale | 2,945 | 15.77 | $46,443 | 11,324 | Form 4 |
| 2026-03-05 | Paravasthu MukundChief Operating Officer | Sale | 43,246 | 13.77 | $595,497 | 72,832 | Form 4 |
| 2026-03-04 | Weinberg UriChf Medical and Innovation Ofr | Sale | 6,412 | 13.31 | $85,344 | 267,190 | Form 4 |
| 2026-03-04 | Leonard Frank XChief Executive Officer | Sale | 5,607 | 13.31 | $74,629 | 493,793 | Form 4 |
| 2026-03-04 | Puri Michal NathChief Human Resources Officer | Sale | 1,100 | 13.31 | $14,641 | 201,322 | Form 4 |
| 2026-03-04 | Leupin NicolasFormer Chief Medical Officer | Sale | 1,100 | 13.31 | $14,641 | 102,979 | Form 4 |
| 2026-03-04 | Paravasthu MukundChief Operating Officer | Sale | 5,377 | 13.31 | $71,568 | 116,078 | Form 4 |
| 2026-03-04 | Brackmann ChristophChief Financial Officer | Sale | 6,412 | 13.31 | $85,344 | 182,842 | Form 4 |
| 2026-03-03 | Doyle William FDirector, Executive Chairman | Sale | 50,557 | 12.79 | $646,624 | 349,727 | Form 4 |
| 2026-03-03 | Doyle William FDirector, Executive Chairman | Sale | 21,330 | 13.43 | $286,462 | 328,397 | Form 4 |
| 2026-03-02 | Weinberg UriChf Medical and Innovation Ofr | Sale | 3,272 | 13.33 | $43,616 | 223,477 | Form 4 |
| 2026-03-02 | Leonard Frank XChief Executive Officer | Sale | 7,232 | 13.49 | $97,560 | 349,400 | Form 4 |
| 2026-03-02 | Paravasthu MukundChief Operating Officer | Sale | 408 | 13.49 | $5,504 | 76,343 | Form 4 |
| 2026-02-27 | Weinberg UriChf Medical and Innovation Ofr | Sale | 7,461 | 13.84 | $103,260 | 213,757 | Form 4 |
| 2026-02-27 | Leonard Frank XChief Executive Officer | Sale | 9,734 | 13.66 | $132,966 | 338,011 | Form 4 |
| 2026-02-27 | Puri Michal NathChief Human Resources Officer | Sale | 1,441 | 13.66 | $19,684 | 162,322 | Form 4 |
| 2026-02-27 | Leupin NicolasFormer Chief Medical Officer | Sale | 1,029 | 13.66 | $14,056 | 104,079 | Form 4 |
| 2026-02-27 | Paravasthu MukundChief Operating Officer | Sale | 1,555 | 13.66 | $21,241 | 76,751 | Form 4 |
| 2025-09-05 | Cordova AshleyChief Executive Officer | Buy | 81,550 | 12.22 | $996,541 | 437,569 | Form 4 |
| 2025-07-29 | Brackmann ChristophChief Financial Officer | Buy | 10,000 | 11.63 | $116,300 | 131,150 | Form 4 |
| 2025-07-29 | Brackmann ChristophChief Financial Officer | Buy | 5,000 | 11.60 | $58,000 | 136,150 | Form 4 |
| 2025-07-29 | Brackmann ChristophChief Financial Officer | Buy | 5,000 | 11.50 | $57,500 | 141,150 | Form 4 |
| 2025-06-03 | Hung DavidDirector | Sale | 999 | 17.30 | $17,283 | 12,195 | Form 4 |
| 2025-06-03 | Vernon W AnthonyDirector | Sale | 999 | 17.35 | $17,333 | 167,887 | Form 4 |
| 2025-06-03 | Ocean Allyson JDirector | Sale | 999 | 17.29 | $17,273 | 3,054 | Form 4 |
| 2025-06-03 | Hilleman Jeryl LDirector | Sale | 999 | 17.26 | $17,243 | 5,591 | Form 4 |
| 2025-06-03 | Scannell Timothy JDirector | Sale | 999 | 17.32 | $17,303 | 6,018 | Form 4 |
| 2025-06-03 | Madden Martin J.Director | Sale | 999 | 17.19 | $17,173 | 18,674 | Form 4 |
| 2025-06-03 | Leung GabrielDirector | Sale | 999 | 17.31 | $17,293 | 81,229 | Form 4 |
| 2025-06-03 | Stafford KristinDirector | Sale | 999 | 17.28 | $17,263 | 3,054 | Form 4 |
| 2025-06-02 | Leonard Frank XEVP, Pres., Novocure Oncology | Saleplan | 21,717 | 17.22 | $373,967 | 176,931 | Form 4 |
| 2025-06-02 | Leonard Frank XEVP, Pres., Novocure Oncology | Saleplan | 6,600 | 17.99 | $118,734 | 170,331 | Form 4 |
| 2025-06-02 | Leonard Frank XEVP, Pres., Novocure Oncology | Saleplan | 1,879 | 19.01 | $35,720 | 168,452 | Form 4 |
25 more
| 2025-05-03 | Paravasthu MukundChief Operating Officer | Sale | 592 | 17.91 | $10,603 | 83,556 | Form 4 |
| 2025-03-03 | Paravasthu MukundChief Operating Officer | Sale | 250 | 18.54 | $4,635 | 29,173 | Form 4 |
| 2025-03-03 | Cordova AshleyChief Executive Officer | Sale | 2,053 | 18.54 | $38,063 | 204,005 | Form 4 |
| 2025-03-03 | Leonard Frank XEVP, Pres., Novocure Oncology | Sale | 2,527 | 18.54 | $46,851 | 143,673 | Form 4 |
| 2025-03-03 | Weinberg UriChief Innovation Officer | Sale | 268 | 18.92 | $5,071 | 166,243 | Form 4 |
| 2025-02-28 | Paravasthu MukundChief Operating Officer | Sale | 368 | 18.28 | $6,727 | 29,423 | Form 4/A |
| 2025-02-28 | Leonard Frank XEVP, Pres., Novocure Oncology | Sale | 2,770 | 18.28 | $50,636 | 146,200 | Form 4/A |
| 2025-02-28 | Cordova AshleyChief Executive Officer | Sale | 2,341 | 18.28 | $42,793 | 206,058 | Form 4/A |
| 2025-02-28 | Weinberg UriChief Innovation Officer | Sale | 4,326 | 18.78 | $81,242 | 166,822 | Form 4/A |
| 2025-02-28 | Weinberg UriChief Innovation Officer | Sale | 311 | 18.31 | $5,694 | 166,511 | Form 4/A |
| 2025-02-27 | Paravasthu MukundChief Operating Officer | Sale | 1,379 | 19.92 | $27,470 | 30,058 | Form 4/A |
| 2025-02-27 | Paravasthu MukundChief Operating Officer | Sale | 267 | 20.55 | $5,487 | 29,791 | Form 4/A |
| 2025-02-27 | Leupin NicolasChief Medical Officer | Sale | 830 | 19.92 | $16,534 | 50,294 | Form 4/A |
| 2025-02-27 | Leupin NicolasChief Medical Officer | Sale | 161 | 20.55 | $3,309 | 50,133 | Form 4/A |
| 2025-02-27 | Puri Michal NathChief Human Resources Officer | Sale | 1,162 | 19.92 | $23,147 | 108,931 | Form 4/A |
| 2025-02-27 | Puri Michal NathChief Human Resources Officer | Sale | 225 | 20.55 | $4,624 | 108,706 | Form 4/A |
| 2025-02-27 | Leonard Frank XEVP, Pres., Novocure Oncology | Sale | 10,277 | 19.92 | $204,718 | 150,959 | Form 4/A |
| 2025-02-27 | Leonard Frank XEVP, Pres., Novocure Oncology | Sale | 1,989 | 20.55 | $40,874 | 148,970 | Form 4/A |
| 2025-02-27 | Cordova AshleyChief Executive Officer | Sale | 9,345 | 19.92 | $186,152 | 210,207 | Form 4/A |
| 2025-02-27 | Cordova AshleyChief Executive Officer | Sale | 1,808 | 20.55 | $37,154 | 208,399 | Form 4/A |
| 2025-01-11 | Paravasthu MukundChief Operating Officer | Sale | 2,160 | 26.81 | $57,910 | 31,437 | Form 4 |
| 2024-11-02 | Paravasthu MukundChief Operating Officer | Sale | 44 | 16.69 | $734 | 3,459 | Form 4 |
| 2024-11-01 | Paravasthu MukundChief Operating Officer | Sale | 160 | 15.88 | $2,541 | 3,503 | Form 4 |
| 2024-11-01 | Leonard Frank XEVP, Pres., Novocure Oncology | Sale | 598 | 15.94 | $9,532 | 161,236 | Form 4 |
| 2024-10-31 | Puri Michal NathChief Human Resources Officer | Sale | 810 | 15.79 | $12,790 | 110,093 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
53 × grant or award10 × shares withheld for tax1 × option exercise
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Danziger AsafDirector | Grant or award A | +268 | 11.15 | 416,742 | Form 4 |
| 2026-06-30 | Leonard Frank XChief Executive Officer | Grant or award A | +1,905 | 11.15 | 461,425 | Form 4 |
| 2026-06-30 | Ben Arye BarakGeneral Counsel | Grant or award A | +1,299 | 11.15 | 243,752 | Form 4 |
| 2026-06-30 | Puri Michal NathChief Human Resources Officer | Grant or award A | +1,905 | 11.15 | 203,227 | Form 4 |
| 2026-06-03 | Hilleman Jeryl LDirector | Grant or award A | +11,610 | – | 25,471 | Form 4 |
| 2026-06-03 | Leung GabrielDirector | Grant or award A | +11,610 | – | 101,109 | Form 4 |
| 2026-06-03 | Hung DavidDirector | Grant or award A | +11,610 | – | 32,075 | Form 4 |
| 2026-06-03 | Vernon W AnthonyDirector | Grant or award A | +11,610 | – | 209,267 | Form 4 |
| 2026-06-03 | Scannell Timothy JDirector | Grant or award A | +11,610 | – | 25,898 | Form 4 |
| 2026-06-03 | Madden Martin J.Director | Grant or award A | +11,610 | – | 30,284 | Form 4 |
| 2026-06-03 | Ocean Allyson JDirector | Grant or award A | +11,610 | – | 22,934 | Form 4 |
| 2026-06-03 | Stafford KristinDirector | Grant or award A | +11,610 | – | 22,934 | Form 4 |
| 2026-04-28 | Vernon W AnthonyDirector | Option exercise M | +21,500 | 11.39 | 200,602 | Form 4 |
| 2026-03-04 | Cordova AshleyFormer Chief Executive Officer | Shares withheld for tax F | −17,638 | 13.30 | 422,570 | Form 4 |
| 2026-03-03 | Doyle William FDirector, Executive Chairman | Grant or award A | +200,000 | – | 200,000 | Form 4 |
| 2026-03-03 | Doyle William FDirector, Executive Chairman | Grant or award A | +200,284 | – | 400,284 | Form 4 |
| 2026-03-03 | Weinberg UriChf Medical and Innovation Ofr | Grant or award A | +50,125 | – | 273,602 | Form 4 |
| 2026-03-03 | Leonard Frank XChief Executive Officer | Grant or award A | +150,000 | – | 499,400 | Form 4 |
| 2026-03-03 | Ben Arye BarakGeneral Counsel | Grant or award A | +50,125 | – | 242,453 | Form 4 |
| 2026-03-03 | Puri Michal NathChief Human Resources Officer | Grant or award A | +40,100 | – | 202,422 | Form 4 |
| 2026-03-03 | Paravasthu MukundChief Operating Officer | Grant or award A | +45,112 | – | 121,455 | Form 4 |
| 2026-03-03 | Brackmann ChristophChief Financial Officer | Grant or award A | +55,137 | – | 189,254 | Form 4 |
| 2026-03-02 | Cordova AshleyFormer Chief Executive Officer | Shares withheld for tax F | −2,410 | 13.67 | 447,436 | Form 4 |
| 2026-03-02 | Cordova AshleyFormer Chief Executive Officer | Shares withheld for tax F | −7,228 | 13.67 | 440,208 | Form 4 |
| 2026-02-28 | Weinberg UriChf Medical and Innovation Ofr | Grant or award A | +12,992 | – | 226,749 | Form 4 |
| 2026-02-28 | Cordova AshleyFormer Chief Executive Officer | Grant or award A | +23,818 | – | 449,846 | Form 4 |
| 2026-02-28 | Leonard Frank XChief Executive Officer | Grant or award A | +18,621 | – | 356,632 | Form 4 |
| 2026-02-28 | Ben Arye BarakGeneral Counsel | Grant or award A | +17,755 | – | 192,328 | Form 4 |
| 2026-02-27 | Cordova AshleyFormer Chief Executive Officer | Shares withheld for tax F | −11,541 | 13.75 | 426,028 | Form 4 |
| 2026-01-11 | Paravasthu MukundChief Operating Officer | Shares withheld for tax F | −2,133 | 14.35 | 78,306 | Form 4 |
| 2025-12-31 | Danziger AsafDirector | Grant or award A | +1 | 10.99 | 416,474 | Form 5 |
| 2025-12-31 | Ben Arye BarakGeneral Counsel | Grant or award A | +108 | 10.99 | 174,573 | Form 5 |
| 2025-12-31 | Puri Michal NathChief Human Resources Officer | Grant or award A | +1 | 10.99 | 163,763 | Form 5 |
| 2025-11-04 | Paravasthu MukundChief Operating Officer | Shares withheld for tax F | −2,949 | 12.23 | 80,439 | Form 4 |
| 2025-11-04 | Brackmann ChristophChief Financial Officer | Shares withheld for tax F | −7,033 | 12.23 | 134,117 | Form 4 |
| 2025-11-01 | Leonard Frank XEVP, Pres., Novocure Oncology | Shares withheld for tax F | −966 | 12.81 | 347,745 | Form 4 |
| 2025-11-01 | Paravasthu MukundChief Operating Officer | Shares withheld for tax F | −168 | 12.81 | 83,388 | Form 4 |
| 2025-10-31 | Puri Michal NathChief Human Resources Officer | Shares withheld for tax F | −752 | 12.82 | 163,762 | Form 4 |
| 2025-06-30 | Ben Arye BarakGeneral Counsel | Grant or award A | +769 | 15.13 | 174,465 | Form 4 |
| 2025-06-30 | Cordova AshleyChief Executive Officer | Grant or award A | +833 | 15.13 | 356,019 | Form 4 |
| 2025-06-30 | Danziger AsafDirector | Grant or award A | +833 | 15.13 | 416,473 | Form 4 |
| 2025-06-30 | Leonard Frank XEVP, Pres., Novocure Oncology | Grant or award A | +833 | 15.13 | 348,711 | Form 4 |
| 2025-06-30 | Puri Michal NathChief Human Resources Officer | Grant or award A | +833 | 15.13 | 164,514 | Form 4 |
| 2025-06-04 | Leonard Frank XEVP, Pres., Novocure Oncology | Grant or award A | +179,426 | – | 347,878 | Form 4 |
| 2025-06-04 | Vernon W AnthonyDirector | Grant or award A | +11,215 | – | 179,102 | Form 4 |
| 2025-06-04 | Hung DavidDirector | Grant or award A | +11,215 | – | 23,410 | Form 4 |
| 2025-06-04 | Scannell Timothy JDirector | Grant or award A | +11,215 | – | 17,233 | Form 4 |
| 2025-06-04 | Ocean Allyson JDirector | Grant or award A | +11,215 | – | 14,269 | Form 4 |
| 2025-06-04 | Hilleman Jeryl LDirector | Grant or award A | +11,215 | – | 16,806 | Form 4 |
| 2025-06-04 | Stafford KristinDirector | Grant or award A | +11,215 | – | 14,269 | Form 4 |
| 2025-06-04 | Leung GabrielDirector | Grant or award A | +11,215 | – | 92,444 | Form 4 |
| 2025-03-04 | Cordova AshleyChief Executive Officer | Grant or award A | +151,181 | 18.19 | 355,186 | Form 4 |
| 2025-03-04 | Paravasthu MukundChief Operating Officer | Grant or award A | +54,975 | 18.19 | 84,148 | Form 4 |
| 2025-03-04 | Leonard Frank XEVP, Pres., Novocure Oncology | Grant or award A | +54,975 | 18.19 | 198,648 | Form 4 |
| 2025-03-04 | Weinberg UriChief Innovation Officer | Grant or award A | +54,975 | 18.19 | 221,218 | Form 4 |
| 2025-03-04 | Puri Michal NathChief Human Resources Officer | Grant or award A | +54,975 | 18.19 | 163,681 | Form 4 |
| 2025-03-04 | Ben Arye BarakGeneral Counsel | Grant or award A | +54,975 | 18.19 | 173,696 | Form 4 |
| 2025-03-04 | Leupin NicolasChief Medical Officer | Grant or award A | +54,975 | 18.19 | 105,108 | Form 4 |
| 2025-03-04 | Brackmann ChristophChief Financial Officer | Grant or award A | +54,975 | 18.19 | 121,150 | Form 4 |
| 2025-01-01 | Danziger AsafDirector | Grant or award A | +400,000 | – | 415,640 | Form 4 |
| 2024-12-31 | Danziger AsafDirector | Grant or award A | +412 | 14.75 | 15,640 | Form 4 |
| 2024-12-31 | Cordova AshleyChief Executive Officer | Grant or award A | +373 | 14.75 | 219,552 | Form 4 |
| 2024-12-31 | Ben Arye BarakGeneral Counsel | Grant or award A | +669 | 14.75 | 118,721 | Form 4 |
| 2024-11-04 | Paravasthu MukundChief Operating Officer | Grant or award A | +30,138 | – | 33,597 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.